References of "Withofs, Nadia"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailRADIONUCLIDE IMAGING OF INFECTIVE ENDOCARDITIS: state of art and future perspective
MARCHETTA, Stella ULiege; WITHOFS, Nadia ULiege; ERBA, Paola Anna et al

in Current Cardiovascular Imaging Reports (2017), 10(27),

Detailed reference viewed: 24 (1 ULiège)
Full Text
Peer Reviewed
See detailA First Report on [(18)F]FPRGD2 PET/CT Imaging in Multiple Myeloma.
WITHOFS, Nadia ULiege; Cousin, Francois; DE PRIJCK, Bernard ULiege et al

in Contrast Media & Molecular Imaging (2017), 2017

An observational study was set up to assess the feasibility of [(18)F]FPRGD2 PET/CT for imaging patients with multiple myeloma (MM) and to compare its detection rate with low dose CT alone and combined ... [more ▼]

An observational study was set up to assess the feasibility of [(18)F]FPRGD2 PET/CT for imaging patients with multiple myeloma (MM) and to compare its detection rate with low dose CT alone and combined [(18)F]NaF/[(18)F]FDG PET/CT images. Four patients (2 newly diagnosed patients and 2 with relapsed MM) were included and underwent whole-body PET/CT after injection of [(18)F]FPRGD2. The obtained images were compared with results of low dose CT and already available results of a combined [(18)F]NaF/[(18)F]FDG PET/CT. In total, 81 focal lesions (FLs) were detected with PET/CT and an underlying bone destruction or fracture was seen in 72 (89%) or 8 (10%) FLs, respectively. Fewer FLs (54%) were detected by [(18)F]FPRGD2 PET/CT compared to low dose CT (98%) or [(18)F]NaF/[(18)F]FDG PET/CT (70%) and all FLs detected with [(18)F]FPRGD2 PET were associated with an underlying bone lesion. In one newly diagnosed patient, more [(18)F]FPRGD2 positive lesions were seen than [(18)F]NaF/[(18)F]FDG positive lesions. This study suggests that [(18)F]FPRGD2 PET/CT might be less useful for the detection of myeloma lesions in patients with advanced disease as all FLs with [(18)F]FPRGD2 uptake were already detected with CT alone. [less ▲]

Full Text
Peer Reviewed
See detailMolecular mechanisms, current management and next generation therapy in myeloma bone disease.
Heusschen, Roy ULiege; Muller, Joséphine ULiege; Duray, Elodie ULiege et al

in Leukemia & Lymphoma (2017), S9

Multiple myeloma (MM) bone disease is a major cause of morbidity and mortality in MM patients and persists even in patients in remission. This bone disease is caused by an uncoupling of bone remodeling ... [more ▼]

Multiple myeloma (MM) bone disease is a major cause of morbidity and mortality in MM patients and persists even in patients in remission. This bone disease is caused by an uncoupling of bone remodeling, with increased osteoclast and decreased osteoblast activity and formation, culminating in lytic bone destruction. Bisphosphonates are the current standard of care but new therapies are needed. As the molecular mechanisms controlling MM bone disease are increasingly well understood, new therapeutic targets are extensively explored in the preclinical setting and initial clinical trials with novel compounds now show promising results. In this review, we will provide a comprehensive overview of the biology of MM bone disease, summarize its current clinical management and discuss preclinical and clinical data on next generation therapies. [less ▲]

Detailed reference viewed: 35 (5 ULiège)
Full Text
Peer Reviewed
See detailWhole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group.
Hillengass, J.; Moulopoulos, L. A.; Delorme, S. et al

in Blood cancer journal (2017), 7(8), 599

For decades, conventional skeletal survey (CSS) has been the standard imaging technique for multiple myeloma (MM). However, recently whole-body computed tomography (WBCT) has been implemented into the ... [more ▼]

For decades, conventional skeletal survey (CSS) has been the standard imaging technique for multiple myeloma (MM). However, recently whole-body computed tomography (WBCT) has been implemented into the diagnostic criteria of MM. This analysis compares sensitivity and prognostic significance of WBCT and CSS in patients with smoldering MM (SMM) and MM. Fifty-four of 212 patients (25.5%) had a negative CSS and a positive WBCT for osteolytic lesions (P<0.0001). Of 66 patients with SMM based on CSS, 12 (22.2%) had osteolytic lesions on WBCT. In comparison, WBCT failed to detect some bone destructions in the appendicular skeleton possibly due to limitations of the field of view. Presence of lytic bone lesions in WBCT was of borderline prognostic significance (P=0.051) for SMM patients, with a median time to progression of 38 versus 82 months for those without bone destructions. In conclusion, WBCT identifies significantly more sites of bone destruction than CSS. More than 20% of patients with SMM according to CSS have in fact active MM detectable with WBCT. On the basis of this and other studies, WBCT (either computed tomography (CT) alone or as part of a positron emission tomography-CT protocol) should be considered the current standard for the detection of osteolytic lesions in MM. [less ▲]

Detailed reference viewed: 51 (7 ULiège)
Full Text
Peer Reviewed
See detailMultiple myeloma bone disease: from mechanisms to next generation therapy
Heusschen, Roy ULiege; Muller, Joséphine ULiege; WITHOFS, Nadia ULiege et al

in Belgian Journal of Hematology (2017), 8

Multiple myeloma bone disease is a major cause of morbidity and mortality in multiple myeloma patients and persists even in patients in remission. Multiple myeloma bone disease is caused by an uncoupling ... [more ▼]

Multiple myeloma bone disease is a major cause of morbidity and mortality in multiple myeloma patients and persists even in patients in remission. Multiple myeloma bone disease is caused by an uncoupling of bone remodelling, with increased osteoclast activity and decreased osteoblast activity, culminating in lytic bone destruction. Bisphosphonates are the current standard-of-care but new therapies are needed. As the molecular mechanisms controlling multiple myeloma bone disease are increasingly understood, new therapeutic targets are extensively explored in the preclinical setting and initial clinical trials with novel compounds show promising results. In this review, we provide a comprehensive overview of the biology of multiple myeloma bone disease, summarise its current clinical management and discuss preclinical and clinical data on next generation therapies. [less ▲]

Detailed reference viewed: 67 (8 ULiège)
Full Text
Peer Reviewed
See detailA case of added value of 123I-mIBG SPECT/CT imaging in the diagnosis of a pheochromocytoma extending into the left adrenal vein
PAQUES, Florence ULiege; HAMOIR, Etienne ULiege; LOVINFOSSE, Pierre ULiege et al

in Acta Chirurgica Belgica (2016)

We present the case of a 48-year-old patient with a left adrenal incidentaloma found on computed tomography (CT) for which the diagnosis of pheochromocytoma was confirmed by a 24-hour urinary dosage of ... [more ▼]

We present the case of a 48-year-old patient with a left adrenal incidentaloma found on computed tomography (CT) for which the diagnosis of pheochromocytoma was confirmed by a 24-hour urinary dosage of norepinephrine. The 123I-mIBG scintigraphy showed a high uptake of 123I-mIBG in the left adrenal gland and, additionally, the single photon emission computed tomography combined with a low-dose CT (SPECT/CT) suggested the extension into the adrenal vein. The diagnostic CT and magnetic resonance images agreed with these findings and the subsequent surgery confirmed the vascular invasion. [less ▲]

Detailed reference viewed: 23 (4 ULiège)
Full Text
Peer Reviewed
See detailComparison of combined whole-body 18F-NAF and 18F-FDG PET/CT versus MRI for the detection of myeloma lesions
WITHOFS, Nadia ULiege; COUSIN, François ULiege; TANCREDI, Tino et al

Conference (2016, June 14)

Objectives Imaging requirements for the diagnosis of multiple myeloma (MM) recently changed and 蠅 1 osteolytic bone destruction (蠅 5 mm in size) seen on whole-body (WB) low-dose computed tomography (ldCT ... [more ▼]

Objectives Imaging requirements for the diagnosis of multiple myeloma (MM) recently changed and 蠅 1 osteolytic bone destruction (蠅 5 mm in size) seen on whole-body (WB) low-dose computed tomography (ldCT) or positron emission tomography combined with CT (PET/CT) does fulfill the criteria for bone disease. The present work assessed the lesion detection rate of WB combined [18F]NaF and [18F]FDG PET/CT versus ldCT alone and MRI in patients with newly diagnosed MM. Methods Patients with newly diagnosed MM, prospectively included, underwent WB (from vertex to toes) XR, MRI and combined [18F]NaF and [18F]FDG PET/CT (median delay between scans: 6 days). PET/CT scans were acquired after injection of 134 ± 13 MBq [18F]NaF and 249 ± 18 MBq [18F]FDG (median uptake time: 64 min). The ldCT (3 mm slice thickness; 120 kV; 50-80 mAs) followed by PET emission scan (90 seconds per bed position) were performed. The MR images were acquired in coronal planes in T1-weighted and T2-weighted short-tau inversion recovery. Diffusion-weighted with background suppression images were acquired in the axial plane and reconstructed on coronal planes. PET and LdCT images were reviewed by 2 experienced nuclear medicine physicians and 1 radiologist to detect focal lesions (FLs) and/or diffuse bone marrow involvement. The focal areas of visually detectable increased tracers’ uptake were considered as PET FLs. The MR, ldCT alone and XR images were analyzed by 3 radiologists blinded to each other and to PET/CT results. The FLs were classified according to their location: pelvis, skull, limbs, spine, ribs and one location including the sternum, scapula and clavicles. The McNemar’s test was used to compare the detection rate of each technique and the Kruskal-Wallis test was used to estimate a relationship between the detection rate and the size of FLs measured with ldCT. Results Out of 14 patients initially included, two were excluded (one for a delay > 40 days with XR and one who experienced claustrophobia during MRI acquisition). Twelve myeloma patients (median age 64y) with stage 1 (n = 4), 2 (n = 5) or 3 (n = 3) were included in the analyses. The pattern of bone marrow involvement was focal (n = 7) or combined diffuse and focal (n = 5). Per patient, 1-3 FL (n = 4), 4-10 FLs (n = 2) or > 10 FLs (n = 6) were detected. The total number of FLs detected was 281; no extramedullary disease was detected. The detection rate of MM lesions between techniques was significantly different (p < 0.05): XR (89; 32%) < PET (158; 56%) < MRI (183, 65%) < LdCT alone (219; 78%) < PET/CT (277; 99%). Out of 158 FLs detected with PET, 125 (79%) were also detected with MRI. Out of 183 MM lesions detected with MRI, 125 (68%) were detected with PET; PET positivity was significantly associated with lesion size (p = 0.002). Out of 145 FLs (蠅 5 mm) detected with ldCT, the detection rate of MRI (n = 87; 60%) and PET (n = 96; 66%) was similar (p = 0.17) and significantly associated with lesion size only for MRI (p = 0.014). Whatever FLs location, the detection rate of PET and MRI was similar except for rib MM lesions for which PET was superior to MRI (p = 0.0005). Seventeen osteolytic rib lesions detected with PET were not detected with MRI, of which only one corresponded to a pathologic fracture. At the patient’s level, the diagnosis of MM was based on biological data in 7/12 patients. For the 5 remaining patients, MM diagnosis required imaging. PET/CT and ldCT alone correctly identified bone involvement in all 5 patients; MRI would have missed the correct MM diagnosis in 3 patients (2 with diffuse pattern only and one with 1 FL); WBXR would have missed MM diagnosis in 1/5 patient (one pelvic FL missed). Conclusions The MM lesion detection rate of PET/CT was superior to ldCT alone and MRI, respectively. At the patient’s level, the accuracy of PET/CT and CT alone was superior to MRI and WB-XR for the diagnosis of MM. [less ▲]

Detailed reference viewed: 26 (0 ULiège)
Full Text
Peer Reviewed
See detailIntegrin αvβ3 and RGD-based radiopharmaceuticals
WITHOFS, Nadia ULiege; HUSTINX, Roland ULiege

in Médecine Nucléaire : Imagerie Fonctionnelle et Métabolique (2016), 40 (2016)

Positron emission tomography combined with computed tomography (PET/CT) using RGD-based radiopharmaceuticals allows quantification of tumour expression of integrin αvβ3 in vivo. Integrins and, in ... [more ▼]

Positron emission tomography combined with computed tomography (PET/CT) using RGD-based radiopharmaceuticals allows quantification of tumour expression of integrin αvβ3 in vivo. Integrins and, in particular, integrin αvβ3 are involved in numerous physiologic and pathologic processes, including angiogenesis. RGD-based radiopharmaceuticals targeting integrin αvβ3, expressed by activated endothelial cells, have been developed in order to quantify angiogenesis. However, integrin αvβ3 is also frequently expressed by tumour cells and/or tumour microenvironment cells, e.g., bone marrow derived cells and osteoclasts in bone. Upregulation of integrin αvβ3 by tumour cells promotes cell survival, proliferation, invasion, metastasis and resistance to treatment. Therefore, the PET signal related to RGD-based radiopharmaceuticals may not reflect angiogenesis only. Moreover, tumours may develop mechanisms other than angiogenesis to ensure blood supply such as vascular mimicry, vessel co-option and intussusceptive angiogenesis that might not be assessed with RGD PET/CT. In the setting of treatment assessment, a drop of the RGD PET signal certainly means tumour response (endothelial and/or tumour cell apoptosis and/or vessel normalisation). On the other hand, a stable or increased RGD PET signal may be related to absence of response or upregulation of integrin αvβ3 in adaptative response to therapy, promoting resistance. This review illustrates the complexity of the role of integrin αvβ3 in oncology and its role in non-oncologic diseases such as osteoarthtitis and cardiovascular diseases. [less ▲]

Detailed reference viewed: 50 (16 ULiège)
Full Text
Peer Reviewed
See detailRecommendations to stage and assess the response to therapy of lymphomas with [18F]FDG-PET-CT
Barrington, S. F.; Fosse, P.; WITHOFS, Nadia ULiege et al

in Médecine Nucléaire (2016), 40(1), 55-64

Abstract Mounting evidence supports the major role of [18F]FDG PET-CT in the assessment of response to chemotherapy in lymphoma. The five-point scale to grade response is becoming widely used both in ... [more ▼]

Abstract Mounting evidence supports the major role of [18F]FDG PET-CT in the assessment of response to chemotherapy in lymphoma. The five-point scale to grade response is becoming widely used both in practice and response-adapted trials. In 2014, a malignant lymphomas imaging working group composed of representatives from major international cooperative groups published revised guidelines concerning the role of imaging in the staging and response assessment of lymphoma. This paper summarizes the main recommendations to facilitate their clinical routine applications. [less ▲]

Detailed reference viewed: 17 (0 ULiège)
Full Text
Peer Reviewed
See detailMultimodality imaging assessment of the deleterious role of the intraluminal thrombus on the growth of abdominal aortic aneurysm in a rat model
NCHIMI LONGANG, Alain ULiege; Courtois, Audrey ULiege; EL HACHEMI, Mounia ULiege et al

in European Radiology (2016), 26

Objectives To evaluate imaging changes occurring in a rat model of elastase-induced abdominal aortic aneurysm (AAA), with emphasis on the intraluminal thrombus (ILT) occurrence. Methods The post-induction ... [more ▼]

Objectives To evaluate imaging changes occurring in a rat model of elastase-induced abdominal aortic aneurysm (AAA), with emphasis on the intraluminal thrombus (ILT) occurrence. Methods The post-induction growth of the AAA diameter was characterized using ultrasound in 22 rats. ILT was reported on 13 rats that underwent 14 magnetic resonance imaging (MRI) 2-18 days post-surgery, and on 10 rats that underwent 18 fluoro-deoxyglucose (FDG) positron emission tomography (PET)/microcomputed tomography examinations 2-27 days post-surgery. Logistic regressions were used to establish the evolution with time of AAA length, diameter, ILT thickness, volume, stratification, MRI and FDG PET signalling properties, and histological assessment of inflammatory infiltrates. Results All of the following significantly increased with time post-induction (p < 0.001): AAA length, AAA diameter, ILT maximal thickness, ILT volume, ILT iron content and related MRI signalling changes, quantitative uptake on FDG PET, and the magnitude of inflammatory infiltrates on histology. However, the aneurysm growth peak followed occurrence of ILT approximately 6 days after elastase infusion. Conclusion Our model emphasizes that occurrence of ILT precedes AAA peak growth. Aneurysm growth is associated with increasing levels of iron, signalling properties changes in both MRI and FDG PET, relating to its biological activities. [less ▲]

Detailed reference viewed: 46 (18 ULiège)
Full Text
Peer Reviewed
See detail[18F]FPRGD2 PET/CT imaging of integrin αvβ3 levels in patients with locally advanced rectal carcinoma
WITHOFS, Nadia ULiege; Martinive, Philippe ULiege; VANDERICK, Jean ULiege et al

in European journal of nuclear medicine and molecular imaging (2016)

PURPOSE: Our primary objective was to determine if [18F]FPRGD2 PET/CT performed at baseline and/or after chemoradiotherapy (CRT) could predict tumour regression grade (TRG) in locally advanced rectal ... [more ▼]

PURPOSE: Our primary objective was to determine if [18F]FPRGD2 PET/CT performed at baseline and/or after chemoradiotherapy (CRT) could predict tumour regression grade (TRG) in locally advanced rectal cancer (LARC). Secondary objectives were to compare baseline [18F]FPRGD2 and [18F]FDG uptake, to evaluate the correlation between posttreatment [18F]FPRGD2 uptake and tumour microvessel density (MVD) and to determine if [18F]FPRGD2 and FDG PET/CT could predict disease-free survival. METHODS: Baseline [18F]FPRGD2 and FDG PET/CT were performed in 32 consecutive patients (23 men, 9 women; mean age 63 +/- 8 years) with LARC before starting any therapy. A posttreatment [18F]FPRGD2 PET/CT scan was performed in 24 patients after the end of CRT (median interval 7 weeks, range 3 - 15 weeks) and before surgery (median interval 4 days, range 1 - 15 days). RESULTS: All LARC showed uptake of both [18F]FPRGD2 (SUVmax 5.4 +/- 1.5, range 2.7 - 9) and FDG (SUVmax 16.5 +/- 8, range 7.1 - 36.5). There was a moderate positive correlation between [18F]FPRGD2 and FDG SUVmax (Pearson's r = 0.49, p = 0.0026). There was a moderate negative correlation between baseline [18F]FPRGD2 SUVmax and the TRG (Spearman's r = -0.37, p = 0.037), and a [18F]FPRGD2 SUVmax of >5.6 identified all patients with a complete response (TRG 0; AUC 0.84, 95 % CI 0.68 - 1, p = 0.029). In the 24 patients who underwent a posttreatment [18F]FPRGD2 PET/CT scan the response index, calculated as [(SUVmax1 - SUVmax2)/SUVmax1] x 100 %, was not associated with TRG. Post-treatment [18F]FPRGD2 uptake was not correlated with tumour MVD. Neither [18F]FPRGD2 nor FDG uptake predicted disease-free survival. CONCLUSION: Baseline [18F]FPRGD2 uptake was correlated with the pathological response in patients with LARC treated with CRT. However, the specificity was too low to consider its clinical routine use. [less ▲]

Detailed reference viewed: 45 (14 ULiège)
Full Text
Peer Reviewed
See detailImaging myeloma and related monoclonal plasma cell disorders using MRI, low dose whole-body CT and FDG PET/CT
WITHOFS, Nadia ULiege; NANNI, C.; SIMONI, Paolo ULiege et al

in Clinical and Translational Imaging (2015), 3

A majority of multiple myeloma patients present with osteolytic bone lesions that can cause bone pain, fractures or hypercalcaemia. Correct identification of these lesions is important in the initial ... [more ▼]

A majority of multiple myeloma patients present with osteolytic bone lesions that can cause bone pain, fractures or hypercalcaemia. Correct identification of these lesions is important in the initial assessment of the disease. <br />Although the radiological skeletal survey is the gold standard to detect bone osteolytic lesions, it may miss small bone lesions or lesions located in the spine or pelvis due to the superimposed images of soft tissues. These limitations propelled newer imaging techniques such as positron emission tomography combined with computed tomography (PET/CT) and magnetic resonance imaging (MRI) in the diagnosis of multiple myeloma. In addition, 18F-fluorodeoxyglucose PET/CT and MRI have prognostic value and can be used to monitor disease. <br />This review discusses the additional value of PET/CT and MRI in the management of MM. [less ▲]

Detailed reference viewed: 56 (31 ULiège)
Full Text
Peer Reviewed
See detail18F-FPRGD2 PET/CT imaging of integrin αvβ3 in renal carcinomas: Correlation with histopathology
WITHOFS, Nadia ULiege; SIGNOLLE, NICOLAS; SOMJA, Joan ULiege et al

in Journal of Nuclear Medicine (The) (2015)

Detailed reference viewed: 59 (16 ULiège)
Full Text
Peer Reviewed
See detail(18)F-FPRGD2 PET/CT imaging of musculoskeletal disorders.
WITHOFS, Nadia ULiege; CHARLIER, Edith ULiege; Simoni, Paolo et al

in Annals of nuclear medicine (2015), 29(10), 839-47

OBJECTIVE: This work reports on musculoskeletal uptake of (18)F-FPRGD2, targeting the integrin alphavbeta3, in patients who had undergone (18)F-FPRGD2 positron emission tomography combined with computed ... [more ▼]

OBJECTIVE: This work reports on musculoskeletal uptake of (18)F-FPRGD2, targeting the integrin alphavbeta3, in patients who had undergone (18)F-FPRGD2 positron emission tomography combined with computed tomography (PET/CT) for oncologic purposes. METHODS: Whole-body (18)F-FPRGD2 PET/CT images of 62 cancer patients were retrospectively reviewed to detect foci of musculoskeletal (18)F-FPRGD2 uptake. For 37 patients, a FDG PET/CT performed in clinical settings was available. In each joint with an abnormal uptake, the maximum standardized uptake value (SUVmax) was estimated. RESULTS: A total of 260 musculoskeletal foci of (18)F-FPRGD2 uptake were detected. Most common sites of uptake were joints and discs (n = 160; 61.5 %), entheses (osteotendinous and osteoligamentous junctions; n = 55; 21.2 %) and recent fractures (n = 18; 6.9 %). In addition, 27 (10.4 %) miscellaneous foci were detected. Out of the 146 lesions for which a FDG PET was available, 63 % showed both (18)F-FPRGD2 and FDG uptake, 33.6 % did not show FDG avidity and 3.4 % showed only FDG uptake. The uptake intensity of the 92 lesions positive with (18)F-FPRGD2 and FDG was similar with both radiopharmaceuticals, but the target-to-background (blood pool or muscle) ratios were significantly higher with (18)F-FPRGD2 than with FDG (p < 0.0001). CONCLUSION: The (18)F-FPRGD2 uptake in joints, spine degenerative diseases and tendons was highly prevalent in our population. Up to one-third of (18)F-FPRGD2 foci showed no FDG uptake suggesting that (18)F-FPRGD2 signal may not be related to inflammatory angiogenesis only. [less ▲]

Detailed reference viewed: 28 (12 ULiège)
Full Text
Peer Reviewed
See detailThe role of positron emission tomography-computed tomography and magnetic resonance imaging in diagnosis and follow-up of multiple myeloma
CAERS, Jo ULiege; WITHOFS, Nadia ULiege; Hillengass, Jens et al

in Haematologica (2014), 99(4), 629-37

Multiple myeloma is the second most common hematologic malignancy and occurs most commonly in elderly patients. Almost all multiple myeloma patients develop bone lesions in the course of their disease or ... [more ▼]

Multiple myeloma is the second most common hematologic malignancy and occurs most commonly in elderly patients. Almost all multiple myeloma patients develop bone lesions in the course of their disease or have evidence of bone loss at initial diagnosis. Whole-body conventional radiography remains the gold standard in the diagnostic evaluation, but computed tomography, magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography are increasingly used as complementary techniques in the detection of bone lesions. Moreover, the number of lesions detected and the presence of extramedullary disease give strong prognostic information. These new techniques may help to assess treatment response in solitary plasmacytoma or in multiple myeloma. In this article, we review recent data on the different imaging techniques used at diagnosis and in the assessment of treatment response, and discuss some current issues. [less ▲]

Detailed reference viewed: 75 (42 ULiège)
Full Text
Peer Reviewed
See detailLe cas clinique du mois : Pseudo-démence dépressive
SCHENA, Anthony; Ansseau, Marc ULiege; TRIFFAUX, Jean-Marc ULiege et al

in Revue Médicale de Liège (2014), 69

Detailed reference viewed: 104 (8 ULiège)
Full Text
Peer Reviewed
See detailUtilisation de l'imagerie fonctionnelle en radiothérapie
LALLEMAND, François ULiege; LAKOSI, Ferenc ULiege; HUSTINX, Roland ULiege et al

in Revue Médicale de Liège (2014), 69(Supp 1), 20-28

Les progrès technologiques réalisés par l’image- rie médicale l’ont placée au centre de la prise en charge des patients oncologiques, tant au niveau du diagnostic, du pro - nostic et du suivi que dans la ... [more ▼]

Les progrès technologiques réalisés par l’image- rie médicale l’ont placée au centre de la prise en charge des patients oncologiques, tant au niveau du diagnostic, du pro - nostic et du suivi que dans la prise en charge thérapeutique. En effet, l’imagerie représente, à l’heure actuelle, la pierre angulaire des traitements de radiothérapie. Les objectifs du radiothérapeute sont d’irradier le plus précisément possible la tumeur à dose curative, tout en évitant les organes sains. Pour y arriver, le radiothérapeute utilise de façon routinière l’imagerie anatomique (Scanner et IRM). Depuis quelques années, le développement des différentes imageries métabo - liques et fonctionnelles, comme l’imagerie par émission de positons (PET-CT) et la résonnance magnétique fonctionnelle, ouvrent de nouvelles possibilités thérapeutiques grâce aux informations qu’elles apportent sur la biologie des tumeurs. Cet article décrit, de manière non exhaustive, les différentes imageries anatomiques et métaboliques à la disposition du radiothérapeute. [less ▲]

Detailed reference viewed: 93 (27 ULiège)
Full Text
Peer Reviewed
See detailImagerie de l'intégrine αvβ3 par PET/CT au 18F-FPRGD2
WITHOFS, Nadia ULiege; HUSTINX, Roland ULiege

in Revue Médicale de Liège (2014), 69(Synthèse 2014), 36-40

Detailed reference viewed: 27 (7 ULiège)
Full Text
Peer Reviewed
See detailFDG PET/CT for rectal carcinoma radiotherapy treatment planning : Comparison of functional volume delineation algorithms and clinical challenges.
WITHOFS, Nadia ULiege; BERNARD, Claire ULiege; VAN DER REST, Catherine ULiege et al

in Journal of Applied Clinical Medical Physics (2014), 15(5), 216-228

PET/CT imaging could improve delineation of rectal carcinoma gross tumor volume (GTV) and reduce interobserver variability. The objective of this work was to compare various functional volume delineation ... [more ▼]

PET/CT imaging could improve delineation of rectal carcinoma gross tumor volume (GTV) and reduce interobserver variability. The objective of this work was to compare various functional volume delineation algorythms. [less ▲]

Detailed reference viewed: 67 (33 ULiège)